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ABSTRACT
To assess the clinical utility of prescribing a sliding scale regimen for methotrexate admin-
istered in cases of persistent ectopic pregnancy, a prospectively designed clinical trial was
performed. Patients (« = 37) previously operated on for ectopic pregnancy by laparoscopic
salpingostomy and found to have persistent disease were enrolled into the study. Methotrex-
ate was given intramuscularly at a dose of 1 mg/kg body weight, with the number of doses
administered depending on the presenting level of serum beta-human chorionic gonadotropin
(/J-hCG). Group 1 (n = 27), levels of 10-1500 mIU/ml, received a single dose; group 2 (n =
5), levels of 1500-2500 mIU/ml, received two doses 3 days apart; group 3 (n = 5), levels
>2500 mIU/ml, received three doses 3 days apart. Patients were followed with weekly trans-
vaginal ultrasound examinations, and serum /3-hCG and progesterone measurements. Re-
sults noted resolution in all three treatment groups without the requirement of surgery or
further treatment: group 1, 19.9 ± 1.7 days; group 2, 35.2 ± 4.5 days; group 3, 49.0 ± 1.0
days. All patients remained asymptomatic, and no adverse side effects from the drug were
experienced. We conclude, although preliminary, that a sliding scale approach to prescrib-
ing methotrexate based on the initial serum titer of ß-hCG to treat persistent ectopic preg-
nancy is easy to use, efficacious, and likely results in complete resolution of the condition.
In most cases, even with presenting levels of /3-hCG > 2500 mIU/ml, persistent disease will
resolve within 50 days of initiating care. (J GYNECOL SURG 13:13, 1997)
INTRODUCTION
The diagnosis and surgical treatment of ectopic pregnancy have been accomplished increasinglythrough the laparoscope. Most tubal gestations, whether ruptured or unruptured, may be successfully
and quickly evacuated through a salpingostomy and removed through a second site port placed in the lower
abdomen.1 This approach obviates the need for performing a laparotomy and reduces surgical morbidity
and patient recovery time.2 Therefore, when it can be safely attempted, the laparoscopic approach optimizes
patient care.3
Despite efforts at completely eradicating the ectopic pregnancy during surgical extirpation, persistent tro-
phoblast proliferation occurs in 5%-10% of cases when a salpingostomy is performed.4,5 Unfortunately, if
left untreated, occasional patients may later rupture their fallopian tube and suffer catastrophic hemorrhage.6
Therefore, once persistent cases are diagnosed, it is best to either reoperate and remove the affected site or
administer methotrexate to destroy the persistent gestation.7
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There is no consensus as to whether surgery or medicine is the better approach for treating persistent dis-
ease. Furthermore, no standard protocol exists for delivering methotrexate to patients with persistent ec-
topic pregnancy following evacuative surgery. Often, women are prescribed drugs in much the same man-
ner as women receiving methotrexate as primary treatment for unruptured ectopic pregnancies.8 Thus,
physicians are often confused as to which regimen to follow and how best to modify published protocols
to suit the needs of the patient.
We devised a protocol for diagnosing and treating persistent cases of ectopic pregnancy based on pat-
terns and titers of serum progesterone and beta-human chorionic gonadotropin (ß
-
hCG).9 This simplified
approach uses an easy to remember sliding scale regimen designed to minimize expensive and time-con-
suming follow-up visits while providing reasonable guidelines for continuing treatment. We report our pre-
liminary experience.
MATERIALS AND METHODS
The use ofmethotrexate for the treatment of persistent ectopic pregnancy in women previously operated
on was reviewed and approved by the Institutional Review Board of the University of Southern California,
Los Angeles. During the course of the 24-month clinical trial, approximately 700 women were treated at
the Los Angeles County-USC Medical Center for ectopic pregnancy. Patients who had recently undergone
laparoscopic salpingostomy for ectopic pregnancy were followed postoperatively using serum measurements
for /3-hCG and progesterone until resolution (/3-hCG < 5.0 mIU/ml; progesterone < 0.5 ng/ml). Patients in
whom persistent disease was documented, as evidenced by elevations in both serum progesterone (>1.5
ng/ml) and /S-hCG (>0.1 X level obtained preoperatively), by the tenth postoperative day were considered
for treatment.9
Subjects (n = 37) were offered medical therapy using methotrexate (1 mg/kg body weight) instead of re-
operation if they met the following entry criteria: asymptomatic, normal liver, renal, and hématologie stud-
ies, agreed to be compliant with follow-up visits, and were desirous of avoiding a second-look procedure.
Transvaginal ultrasound examination of the pelvis was performed before initiating therapy to exclude ad-
nexal pathology and guard against unknowingly treating a heterotopic intrauterine gestation. At the time of
these scans, no patient demonstrated ultrasonographically visible signs of the ectopic sites.
Following informed consent, the women were given methotrexate as a single intramuscular injection. The
dosage and injection schedule was based on the level of /3-hCG exhibited at the time of study entry and
were accordingly grouped. Group 1 subjects had levels of 10-1500 mIU/ml (International Reference Prepa-
ration) and were given a single dose. The range of values for these patients (n = 27) was 55-1450 mIU/ml.
Group 2 (n = 5) levels were 1500-2500 mIU/ml (range 1600-2450 mIU/ml), and patients received a sec-
ond dose intramuscularly 3 days later. Group 3 subjects (n = 5) had values >2500 mIU/ml (range 2500-5500
mIU/ml) and received a third dose 3 days after the second dose, for a total of three doses. Liver function
tests and complete blood counts with platelets were repeated before administering each dose. Weekly vis-
its were scheduled to obtain levels of /3-hCG and progesterone, as well as repeat transvaginal ultrasound
examinations, in order to monitor the progress of subjects following treatment.
RESULTS
The women enrolled for study (n = 37) had all undergone linear salpingostomy performed laparoscopi-
cally by residents in obstetrics and gynecology within 3 weeks of coming for treatment. At diagnosis, all
women were noted to have elevated serum progesterone (mean ± standard error; 3.2 ±1.3 ng/ml) and ß-
hCG levels. Table 1 lists the patients according to treatment group and shows the clinical outcomes.
All women were asymptomatic at the time of persistent proliferation and remained asymptomatic through-
out the treatment and surveillance period. No patient required additional medications beyond that prescribed
by protocol. For each group and in all cases, serum progesterone declined to <0.5 ng/ml within 1 week of
the final dose of methotrexate. In 9 of 10 women receiving more than a single dose of methotrexate, pro-
gesterone remained elevated >1.5 ng/ml before their final injection, implying the need for the additional
drug. Patient compliance was excellent, and all subjects returned for follow-up visits and blood tests. There
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Table 1. Clinical Characteristics of Patients with Persistent Ectopic Gestations
Receiving Varying Doses of Methotrexate Administered by Sliding Scale
Days to resolution (ß-hCG < 5 mW/ml)ß-hCG at diagnosis —.-
Group (mIU/ml; IRP) Mean ± SE Range
1 (n = 27) 10-1500 19.9 ± 1.7 5^t2
2 (n = 5) 1500-2500 35.2 ± 4.5 28-39
3 (n = 5) >2500 49.0 ± 1.0 17-50
were no changes noted in hepatic, renal, or hématologie parameters, and no complications or side effects
occurred during therapy.
DISCUSSION
The treatment of ectopic pregnancy has continued to evolve as diagnostic imaging and serum moni-
toring improve. The ability to discover tubal gestations earlier allows broadening of operative choices
and lessens the need for performing laparotomy. Most cases can be handled laparoscopically, with salp-
ingostomy usually chosen to preserve the tube and maximize fertility potential. This approach is rela-
tively easy to teach, and residents typically learn basic pelviscopic surgery on patients with ectopic preg-
nancy. However, incomplete removal of the trophoblast occurs in 5%-10% oí cases and necessitates a
second procedure or an attempt at medical management. This figure may be even higher in centers with
training programs. Thus, the need for aggressive postoperative surveillance is imperative to ensure good
outcomes.
Treatment of persistent cases of ectopic pregnancy include salpingectomy, repeat salpingostomy, expec-
tant management, and methotrexate therapy.10 In symptomatic patients or in instances in which a large
pelvic mass is sonographically visualized, surgical intervention is indicated. However, this occurs in a mi-
nority of cases. Most patients will remain asymptomatic, and no visible proliferation of trophoblast is evi-
dent on bimanual or ultrasound examination. These women make excellent candidates for nonsurgical in-
tervention, which avoids the expense and morbidity of a second operation.
The dose of methotrexate used in this study and its scheduled delivery were arbitrarily chosen. However,
this regimen closely parallels the amount of drug needed to treat small unimpaired ectopic pregnancies in
our original clinical trial, when the medication was used as primary treatment.11 The mass of viable tro-
phoblast producing ß-hCG is proportional to its serum level, and often more than a single injection of
methotrexate will be necessary. In cases of primary medical management, the more advanced gestations re-
quired the longest duration of treatment and the highest cumulative dose of drug.
The toxicity of methotrexate is primarily related to its duration of use.12 The doses administered in this
trial are consistent with regimens prescribed to women with gestational trophoblastic disease and to proto-
cols used in primary medical management of unruptured ectopic pregnancy.11 Complications are rare, most
often being transient rises in liver enzyme values, and occur in under 10% of patients. Even these untoward
events will be lessened by the proposed dosing schedule of every 3 days rather than consecutive-day de-
livery as was given in the past.
The use of a sliding scale should simplify implementing methotrexate and promote initiation of med-
ical management of persistent disease. By design, this protocol addresses the need to treat the larger more
viable trophoblastic masses aggressively yet delivers drug accordance to a schedule that minimizes toxi-
city. Prescribing methotrexate within a few weeks of surgery should increase patient compliance, as they
are still in the recovery phase of treatment. The few follow-up visits required of medically managed pa-
tients greatly reduce the overall cost of care compared with reoperated patients whether or not outpatient
surgery is used.
We conclude that the use of a standardized protocol for methotrexate prescribed according to a sliding
scale scheduled format will adequately eradicate most, if not all, cases of persistent trophoblastic disease.
A requisite for success is early diagnosis and immediate administration of the drug.
16 Sauer et al. Journal of Gynecologic Surgery
REFERENCES
1. Silva PD. A laparoscopic approach can be applied to most cases of ectopic pregnancy. Obstet Gynecol 1988;72:944.
2. Vermesh M, Silva P, Rosen G, Stein A, Fossum G, Sauer M. Management of unruptured ectopic gestation by lin-
ear salpingostomy: A prospective, randomized clinical trial of laparoscopy versus laparotomy. Obstet Gynecol
1989;73:400.
3. Sauer MV, Rand T, Buster JE. Ectopic pregnancy without laparotomy: Defining the incidence of manageable pa-
tients. Int J Gynecol Obstet 1988;27:247.
4. Bonatz G, Lehmann-Willenbrock E, Kunstmann P, Semm I, Hedderich J, Semm K. Management of patients with
persistent beta-hCG values following laparoscopic surgical and local drug treatment for ectopic pregnancy. Int J
Gynecol Obstet 1994;47:33.
5. Lundorff P, Hahlin M, Sjoblom P, Lindblom B. Persistent trophoblast after conservative treatment of tubal preg-
nancy: Prediction and detection. Obstet Gynecol 1991;77:129.
6. DiMarchi JM, Kosasa TS, Kobara TY, Hale RW. Persistent ectopic pregnancy. Obstet Gynecol 1987;70:555.
7. Rose PG, Cohen SM. Methotrexate therapy for persistent ectopic pregnancy after conservative laparoscopic man-
agement. Obstet Gynecol 1990;76:947.
8. Hoppe DE, Bekkar BE, Nager CW. Single dose systemic methotrexate for the treatment of persistent ectopic preg-
nancy after conservative surgery. Obstet Gynecol 1994;83:51.
9. Vermesh M, Silva P, Sauer MV, Vargyas J, Lobo RA. Persistent tubal ectopic gestation: Patterns of circulating ß-
human chorionic gonadotropin and progesterone, and management options. Fértil Steril 1988;50:584.
10. Cowan BD, McGhee RP, Bates GW. Treatment of persistent ectopic pregnancy with methotrexate and leucovorin
rescue. A case report. Obstet Gynecol 1986;67:50(S).
11. Sauer MV, Gorrill MJ, Rodi IA, et al. Nonsurgical management of unruptured ectopic pregnancy: An extended
clinical trial. Fértil Steril 1987;48:752.
12. Carson SA, Buster JE. Ectopic pregnancy. N Engl J Med 1993;329:1174.
Address reprint requests to:
Mark V. Sauer, M.D.
Columbia Presbyterian Medical Center
Division of Reproductive Endocrinology
622 West 168th Street, PH 16-28
New York, NY 10032-3784
